Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy
The purpose of this study is to determine if IMC-11F8 is safe for patients, and also to determine the best dose of IMC-11F8 to give to patients.
Solid Tumors
BIOLOGICAL: IMC-11F8|BIOLOGICAL: IMC-11F8|BIOLOGICAL: IMC-11F8|BIOLOGICAL: IMC-11F8 I.V.|BIOLOGICAL: IMC-11F8|BIOLOGICAL: IMC-11F8|BIOLOGICAL: IMC-11F8|BIOLOGICAL: IMC-11F8|BIOLOGICAL: IMC-11F8|BIOLOGICAL: IMC-11F8|BIOLOGICAL: IMC-11F8|BIOLOGICAL: IMC-11F8
Number of Participants with Adverse Events, Approximately 24 Months|Maximum Tolerated Dose of IMC-11F8, Approximately 24 Months
Area under the Time Concentration Curve (AUC), Approximately 24 Months|Maximum concentration (Cmax), Approximately 24 Months|Half-life (t 1/2), Approximately 24 Months|Serum Anti-IMC-11F8 Antibody Assessment, Approximately 24 Months|Change from baseline in Antitumor Activity, Approximately 24 Months
The purpose of this study is to establish the safety profile and the maximum tolerated dose (MTD) of the fully human anti-EGFR monoclonal antibody IMC-11F8 in patients with solid tumors who have filed standard therapy or for whom no standard therapy is available.